Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging

Clin Nucl Med. 2015 Apr;40(4):e251-2. doi: 10.1097/RLU.0000000000000586.

Abstract

Erlotinib is a reversible epidermal growth factor receptor tyrosine kinase inhibitor used to treat advanced non-small cell lung carcinoma patients who have shown progression on at least 1 prior chemotherapy regimen. Most of the patients on erlotinib show cutaneous adverse effects. We report the 18F-FDG PET/CT findings in a case of metastatic non-small cell lung carcinoma on erlotinib chemotherapy with developed skin toxicity.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Erlotinib Hydrochloride
  • Fluorodeoxyglucose F18
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Multimodal Imaging
  • Positron-Emission Tomography
  • Quinazolines / adverse effects*
  • Radiopharmaceuticals
  • Skin Diseases / diagnostic imaging*
  • Skin Diseases / etiology
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Erlotinib Hydrochloride